DocSpera Funding: How Much Did They Raise & Key Investors

How Much Did DocSpera Raise?
Funding & Key Investors

DocSpera, a prominent player in the healthcare technology sector, has successfully secured a major strategic investment, bringing its total capital infusion to $10M. This latest financing round, totaling $10M, underscores the company's pivotal role in modernizing surgical workflows and optimizing the complex supply chain associated with implantable medical devices. By attracting significant institutional backing, DocSpera is well-positioned to scale its operations and further penetrate the enterprise healthcare market.

The recent capital injection serves as a testament to the company's robust growth trajectory and its ability to address the critical inefficiencies inherent in surgical coordination. As healthcare providers increasingly shift toward value-based care models, DocSpera's platform provides the necessary infrastructure to streamline clinical operations and enhance patient outcomes through data-driven insights.

What is DocSpera?

DocSpera

Software

Healthcare Software

DocSpera operates as a premier healthcare technology firm specializing in surgical coordination platforms that bridge the gap between surgeons, ambulatory surgery centers (ASCs), and hospitals. The company's solution is designed to automate care coordination and integrate real-time information, effectively managing the substantial spend within the surgical implantable supply market. By maintaining interoperability with over 30 electronic medical record (EMR) systems, DocSpera ensures seamless data capture and workflow integration. This technological foundation allows the company to support the increasing demand for surgical volumes while facilitating the transition to value-based care, positioning it as an essential partner for modern medical institutions seeking to optimize their operational efficiency and clinical performance.

How much funding has DocSpera raised?

DocSpera has raised a total of $10M across 1 funding round:

2022

Series B

$10M

Series B (2022): $10M with participation from JJDC and Pier 70 Ventures

Key Investors in DocSpera

JJDC

JJDC is a strategic investment arm focused on identifying and supporting innovative healthcare technologies that align with long-term clinical and operational advancements.

Pier 70 Ventures

Pier 70 Ventures is an impact-driven investment firm that provides capital and mentorship to high-growth companies, with a specific emphasis on healthcare innovation and sustainable business practices.

What's next for DocSpera?

With the recent influx of capital, DocSpera is poised to accelerate its strategic expansion and deepen its integration within the broader healthcare ecosystem. The company's roadmap likely involves enhancing its predictive analytics capabilities and expanding its network of EMR partnerships to further solidify its market position. As the surgical supply chain continues to evolve, DocSpera's focus on automating complex coordination tasks will be critical in driving long-term value for its enterprise clients. The firm is expected to leverage this investment to scale its sales and engineering teams, ensuring that its platform remains at the forefront of surgical innovation and operational excellence in an increasingly competitive landscape.

See full DocSpera company page

See More Financial Insights